Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Isotechnika Pharma Inc IPHAF

GREY:IPHAF - Post Discussion

Isotechnika Pharma Inc > So what’s going to float ISAs boat?
View:
Post by blog on Aug 12, 2010 10:37am

So what’s going to float ISAs boat?

So, Atriums results for Voclosporin are pushed back to end of 2010 (how convenient is that) + Psoriasis submission in Canada is the same. So, what’s going to float ISAs boat? With any luck at all a new management team will come in with a deal.
Comment by macbethorfaust on Aug 12, 2010 11:27am
 Well, in fact, no deal and ISA is bust.  Whatever deal it is will be tough one.Again, looking for positives though note the comments in the MD&A about the issues taht FDA had. First that is not necessarily the kind of issue that the European agency would use to deny approval - so despite my earlier pessimism there is some hope yet (although I would not yet use the word " ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities